Skip to NavigationSkip to content

Breast Cancer drug

FDA gives accelerated approval to AstraZeneca and Daiichi’s breast cancer drug

The FDA has approved the breast cancer drug Enhertu, developed by AstraZeneca and Daiichi Sankyo.

José Basel, the Executive Vice President of Oncology Research & Development (R&D) at AstraZeneca, said: “With this first approval, we are proud to bring Enhertu to patients with high unmet need and we look forward to further exploring its potential in additional settings.”

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches